Log in

NASDAQ:ACST - Acasti Pharma Stock Price, Forecast & News

$0.56
0.00 (0.00 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$0.55
Now: $0.56
$0.58
50-Day Range
$0.55
MA: $1.01
$2.33
52-Week Range
$0.48
Now: $0.56
$3.08
Volume874,388 shs
Average Volume3.79 million shs
Market Capitalization$50.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACST
CUSIPN/A
Phone45-0687-2262

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share

Profitability

Net Income$-39,290,000.00

Miscellaneous

EmployeesN/A
Market Cap$50.39 million
Next Earnings Date6/24/2020 (Estimated)
OptionableNot Optionable

Receive ACST News and Ratings via Email

Sign-up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.


Acasti Pharma (NASDAQ:ACST) Frequently Asked Questions

What is Acasti Pharma's stock symbol?

Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc (NASDAQ:ACST) posted its quarterly earnings data on Tuesday, January, 15th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. View Acasti Pharma's Earnings History.

When is Acasti Pharma's next earnings date?

Acasti Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, June 24th 2020. View Earnings Estimates for Acasti Pharma.

What price target have analysts set for ACST?

6 Wall Street analysts have issued 1 year price targets for Acasti Pharma's stock. Their forecasts range from $2.00 to $7.00. On average, they anticipate Acasti Pharma's stock price to reach $4.60 in the next year. This suggests a possible upside of 723.5% from the stock's current price. View Analyst Price Targets for Acasti Pharma.

What is the consensus analysts' recommendation for Acasti Pharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acasti Pharma.

What are Wall Street analysts saying about Acasti Pharma stock?

Here are some recent quotes from research analysts about Acasti Pharma stock:
  • 1. According to Zacks Investment Research, "Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada. " (2/20/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $4.96/share, as a 25x multiple of taxed and diluted 2030 EPS of $1.23 discounted back to FY 2020 at 20%; and (b) an NPV discounted cash flow between FY 2020-2030 of $6.32/share, with a discount rate of 13% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/15/2019)

Has Acasti Pharma been receiving favorable news coverage?

News coverage about ACST stock has been trending very positive on Saturday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acasti Pharma earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Acasti Pharma.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,260,000 shares, an increase of 16.5% from the January 15th total of 1,940,000 shares. Based on an average daily volume of 4,370,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.3% of the shares of the stock are sold short. View Acasti Pharma's Current Options Chain.

Who are some of Acasti Pharma's key competitors?

What other stocks do shareholders of Acasti Pharma own?

Who are Acasti Pharma's key executives?

Acasti Pharma's management team includes the folowing people:
  • Ms. Janelle D' Alvise, Pres, CEO & Director
  • Dr. Pierre Lemieux, Co-Founder and Chief Operating & Scientific Officer
  • Mr. Jean-François Boily, VP of Fin.
  • Mr. Brian James Groch, Chief Commercial Officer (Age 52)

Who are Acasti Pharma's major shareholders?

Acasti Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.52%), Oxford Asset Management LLP (0.31%), Barclays PLC (0.11%), Bank of America Corp DE (0.09%), Oppenheimer & Co. Inc. (0.08%) and J. L. Bainbridge & Co. Inc. (0.07%). View Institutional Ownership Trends for Acasti Pharma.

Which major investors are selling Acasti Pharma stock?

ACST stock was sold by a variety of institutional investors in the last quarter, including Private Advisor Group LLC and Mitchell Mcleod Pugh & Williams Inc.. View Insider Buying and Selling for Acasti Pharma.

Which major investors are buying Acasti Pharma stock?

ACST stock was bought by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Renaissance Technologies LLC, Barclays PLC, Bank of America Corp DE, Sargent Investment Group LLC, Sargent Investment Group LLC, Huber Financial Advisors LLC and Schonfeld Strategic Advisors LLC. View Insider Buying and Selling for Acasti Pharma.

How do I buy shares of Acasti Pharma?

Shares of ACST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acasti Pharma's stock price today?

One share of ACST stock can currently be purchased for approximately $0.56.

How big of a company is Acasti Pharma?

Acasti Pharma has a market capitalization of $50.39 million. The biopharmaceutical company earns $-39,290,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. View Additional Information About Acasti Pharma.

What is Acasti Pharma's official website?

The official website for Acasti Pharma is http://www.acastipharma.com/.

How can I contact Acasti Pharma?

Acasti Pharma's mailing address is 545 Promenade du Centropolis Suite 100, Laval A8, H7T 0A3. The biopharmaceutical company can be reached via phone at 45-0687-2262 or via email at [email protected]


MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  499
MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe ACST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel